Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study. [electronic resource]
Producer: 20200909Description: 410-415 p. digitalISSN:- 1473-5741
- Adult
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic -- administration & dosage
- Capecitabine -- administration & dosage
- Dihydrouracil Dehydrogenase (NADP) -- genetics
- Female
- Follow-Up Studies
- Genotype
- Heterozygote
- Humans
- Male
- Middle Aged
- Neoplasms -- drug therapy
- Polymorphism, Single Nucleotide
- Practice Guidelines as Topic -- standards
- Prognosis
- Retrospective Studies
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Observational Study
There are no comments on this title.
Log in to your account to post a comment.